Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
MAIA Biotechnology, Inc. ( (MAIA) ) just unveiled an announcement.
MAIA Biotechnology, Inc. announced the presentation of two posters at the Society for Immunotherapy of Cancer conference in November 2025. The posters detail ongoing Phase 2 and Phase 3 studies of Ateganosine (THIO) in combination with immune checkpoint inhibitors for treating advanced NSCLC resistant to standard therapies, highlighting the company’s commitment to advancing cancer treatment options.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. operates in the biotechnology industry, focusing on developing innovative cancer treatments. The company is engaged in creating therapies that combine Ateganosine (THIO) with immune checkpoint inhibitors to target advanced non-small cell lung cancer (NSCLC) that is resistant to prior treatments.
Average Trading Volume: 579,480
Technical Sentiment Signal: Sell
Current Market Cap: $37.28M
Find detailed analytics on MAIA stock on TipRanks’ Stock Analysis page.